302 related articles for article (PubMed ID: 19837679)
1. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer.
Guiu B; Petit JM; Bonnetain F; Ladoire S; Guiu S; Cercueil JP; Krausé D; Hillon P; Borg C; Chauffert B; Ghiringhelli F
Gut; 2010 Mar; 59(3):341-7. PubMed ID: 19837679
[TBL] [Abstract][Full Text] [Related]
2. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.
Slaughter KN; Thai T; Penaroza S; Benbrook DM; Thavathiru E; Ding K; Nelson T; McMeekin DS; Moore KN
Gynecol Oncol; 2014 Apr; 133(1):11-5. PubMed ID: 24680585
[TBL] [Abstract][Full Text] [Related]
3. Increased visceral to subcutaneous fat ratio is associated with decreased overall survival in patients with metastatic melanoma receiving anti-angiogenic therapy.
Grignol VP; Smith AD; Shlapak D; Zhang X; Del Campo SM; Carson WE
Surg Oncol; 2015 Dec; 24(4):353-8. PubMed ID: 26690825
[TBL] [Abstract][Full Text] [Related]
4. Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents.
Ladoire S; Bonnetain F; Gauthier M; Zanetta S; Petit JM; Guiu S; Kermarrec I; Mourey E; Michel F; Krause D; Hillon P; Cormier L; Ghiringhelli F; Guiu B
Oncologist; 2011; 16(1):71-81. PubMed ID: 21212435
[TBL] [Abstract][Full Text] [Related]
5. Visceral obesity is associated with outcomes of total mesorectal excision for rectal adenocarcinoma.
Ballian N; Lubner MG; Munoz A; Harms BA; Heise CP; Foley EF; Kennedy GD
J Surg Oncol; 2012 Mar; 105(4):365-70. PubMed ID: 21751219
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
Grothey A; Sugrue MM; Purdie DM; Dong W; Sargent D; Hedrick E; Kozloff M
J Clin Oncol; 2008 Nov; 26(33):5326-34. PubMed ID: 18854571
[TBL] [Abstract][Full Text] [Related]
7. Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer.
Miyamoto Y; Oki E; Emi Y; Tokunaga S; Shimokawa M; Ogata Y; Akagi Y; Sakamoto Y; Tanaka T; Saeki H; Maehara Y; Baba H
Anticancer Res; 2018 Jan; 38(1):491-499. PubMed ID: 29277814
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
[TBL] [Abstract][Full Text] [Related]
9. 5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: a single-institute study.
Bir A; Tan W; Wilding GE; Lombardo J; Fakih MG
Oncology; 2007; 72(1-2):4-9. PubMed ID: 17971679
[TBL] [Abstract][Full Text] [Related]
10. Visceral fat and bevacizumab in metastatic colorectal cancer.
Jubb AM
Gut; 2010 Oct; 59(10):1449-50; author reply 1450. PubMed ID: 20650923
[No Abstract] [Full Text] [Related]
11. Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer.
Matsusaka S; Suenaga M; Mishima Y; Takagi K; Terui Y; Mizunuma N; Hatake K
Cancer Chemother Pharmacol; 2011 Sep; 68(3):763-8. PubMed ID: 21170650
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.
Whyte S; Pandor A; Stevenson M; Rees A
Health Technol Assess; 2010 Oct; 14(Suppl. 2):47-53. PubMed ID: 21047491
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
[TBL] [Abstract][Full Text] [Related]
14. Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer.
Vaidyanathan G; Groman A; Wilding G; Fakih MG
Oncology; 2010; 79(1-2):67-71. PubMed ID: 21071992
[TBL] [Abstract][Full Text] [Related]
15. Clinical Impact of Abdominal Fat Distribution on Prognosis After Esophagectomy for Esophageal Squamous Cell Carcinoma.
Okamura A; Watanabe M; Mine S; Nishida K; Imamura Y; Kurogochi T; Kitagawa Y; Sano T
Ann Surg Oncol; 2016 Apr; 23(4):1387-94. PubMed ID: 26668084
[TBL] [Abstract][Full Text] [Related]
16. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
Formica V; Massara MC; Portarena I; Fiaschetti V; Grenga I; Del Vecchio Blanco G; Sileri P; Tosetto L; Skoulidis F; Pallone F; Roselli M
Cancer Biomark; 2009; 5(4):167-75. PubMed ID: 19729826
[TBL] [Abstract][Full Text] [Related]
17. Impact of body mass index and visceral adiposity on outcomes in colorectal cancer.
Yamamoto N; Fujii S; Sato T; Oshima T; Rino Y; Kunisaki C; Masuda M; Imada T
Asia Pac J Clin Oncol; 2012 Dec; 8(4):337-45. PubMed ID: 22897609
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of chemotherapy combined with bevacizumab for metastatic colorectal cancer].
Momoi A; Motomura S; Hashimoto C; Takasaki H; Takemura S; Takagi S; Akaike M
Gan To Kagaku Ryoho; 2011 Jan; 38(1):79-83. PubMed ID: 21368462
[TBL] [Abstract][Full Text] [Related]
19. Body Fatness, Adipose Tissue Compartments, and Biomarkers of Inflammation and Angiogenesis in Colorectal Cancer: The ColoCare Study.
Himbert C; Ose J; Nattenmüller J; Warby CA; Holowatyj AN; Böhm J; Lin T; Haffa M; Gigic B; Hardikar S; Scherer D; Zielske L; Schrotz-King P; Kölsch T; Siegel EM; Shibata D; Ulrich A; Schneider M; Hursting SD; Kauczor HU; Ulrich CM
Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):76-82. PubMed ID: 30333223
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab for metastatic colon cancer: does patient BMI influence survival?
Kaidar-Person O; Badarna H; Bar-Sela G
Anticancer Drugs; 2015 Mar; 26(3):363-6. PubMed ID: 25563769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
